Clinical Trial Update: Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating naltrexone for treatment-emergent fatigue in patients receiving radiation therapy for breast cancer; study terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ
• Fatigue Related to Cancer Treatment
• Invasive Breast Cancer
• Lobular Carcinoma
• Lobular Carcinoma in Situ

Drugs mentioned

• Naltrexone (Naltrexone)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ | Phase 2 | Status: TERMINATED | Results posted: 2021-11-16